Transforming local cancer treatment through smart drug retention
We are developing a differentiated 505(b)(2) product for the local treatment of a difficult-to-manage urothelial cancer affecting the upper urinary tract. The programme combines a well-established anticancer agent with a temperature-responsive delivery system designed to improve drug retention at the site of disease.
This matters because conventional liquid instillations may be rapidly cleared from the urinary tract, limiting contact time between the medicine and the tumour. Patients may therefore require repeated procedures, and some may ultimately face major surgery with significant consequences for renal function and quality of life. Our objective is to create a practical, organ-preserving treatment option that delivers high local exposure while limiting unnecessary systemic exposure.
The product is administered as a liquid through a catheter. At body temperature, the formulation transitions into a semi-solid depot, allowing the active drug to remain in contact with the urothelial surface for an extended period. The depot then gradually dissolves and is eliminated naturally through urinary flow. This localised delivery approach is intended to improve residence time, treatment consistency, and clinical usability.
The underlying therapeutic concept has already been clinically validated through an approved product in the same disease setting. Our programme builds on that regulatory and clinical precedent while pursuing a differentiated formulation, manufacturing process, intellectual property position, and commercial profile.
Work completed to date includes product-concept definition, target product profile development, preliminary formulation assessment, excipient and material selection, patent-landscape review, regulatory pathway analysis, and development-risk evaluation.
The next phase will focus on , in-vitro performance testing, stability studies, process scale-up, container-closure selection, GMP batch manufacture, and regulatory engagement.
About Off Targets Limited
Off Targets Limited is a pharmaceutical innovation company headquartered in London that specializes in the development of complex injectable formulations and the identification of new therapeutic indications for existing drugs. The company utilizes a multidisciplinary approach that combines various artificial intelligence and machine learning platforms with biochemical and cell-based assays. By integrating computational and experimental methodologies, the company aims to create a systematic, logical framework for drug discovery that is more efficient than serendipitous methods. Their R&D operations, which include a presence in Bangalore, India, focus on delivering ready-to-transfer technologies across areas such as central nervous system (CNS) disorders, oncology, and critical care.
This work is particularly significant for addressing unmet medical needs, especially regarding rare, neglected, and difficult-to-treat diseases. By focusing on drug repurposing, the company leverages existing safety, pharmacokinetic, and manufacturing data to expedite the development of innovative medications. This approach provides a streamlined path for bringing specialized treatments to hospital and institutional markets globally. Through its focus on complex injectables and strategic R&D, Off Targets Limited positions itself as a partner for pharmaceutical development, aiming to advance healthcare solutions through its specialized technological capabilities.
delivered to your inbox.